ACB Stock Analysis: Buy, Sell, or Hold?
ACB - Aurora Cannabis Inc. Common Shares
$4.06
-0.02 (-0.49%)
âŧ
5d:
+4.64%
30d:
+4.1%
90d:
+43.46%
WAIT
LOW Confidence
Analysis Updated: Oct 30, 2026 12:00 AM ET
Earnings: Nov 04, 2026
3d
Get Alerted When ACB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ACB is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ACB is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ACB is currently trading at $4.06, which is considered fair relative to its 30-day fair value range of $3.93 to $4.33. From a valuation perspective, the stock is trading at a discount (Forward PE: -676.7) compared to its historical average (43.0). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, ACB is in a strong uptrend. The price is approaching resistance at $4.16. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (18th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $6.23 (+53.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACB is in a strong uptrend. The price is approaching resistance at $4.16. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (18th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $6.23 (+53.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.93 -
$4.33
Company Quality Score
52/100
(HOLD)
Options IV Signal
18th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
77.7%
Protect Your Profits
Holding ACB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 18th percentile)
- NEUTRAL: Mixed technical signals (56/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 53.4% below Wall St target ($6.23)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.93 -
$4.33
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$0.40
(9.9%)
Support & Resistance Levels
Support Level
$3.84
Resistance Level
$4.16
Current Trend
Strong Uptrend
Technical data as of
Oct 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-676.67
Wall Street Target
$6.23
(+53.4%)
Revenue Growth (YoY)
-8.8%
Earnings Growth (YoY)
-94.7%
Profit Margin
-38.2%
PE vs Historical
-676.7 vs 43.0
CHEAP
Share & Embed Analysis
Last updated: October 30, 2026 8:06 PM ET
Data refreshes hourly during market hours. Next update: 9:06 PM
Data refreshes hourly during market hours. Next update: 9:06 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$206 | 47 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 70 BUY |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$30 | 48 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$56 | 31 SELL |
|
AMLX
Amylyx Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
Advanced ACB Option Strategies
Professional options setups generated by AI based on today's ACB price and gamma walls.
